Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population
- PMID: 23555315
- PMCID: PMC3610631
- DOI: 10.1371/journal.pgen.1003419
Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population
Abstract
Rare variation in protein coding sequence is poorly captured by GWAS arrays and has been hypothesized to contribute to disease heritability. Using the Illumina HumanExome SNP array, we successfully genotyped 191,032 common and rare non-synonymous, splice site, or nonsense variants in a multiethnic sample of 2,984 breast cancer cases, 4,376 prostate cancer cases, and 7,545 controls. In breast cancer, the strongest associations included either SNPs in or gene burden scores for genes LDLRAD1, SLC19A1, FGFBP3, CASP5, MMAB, SLC16A6, and INS-IGF2. In prostate cancer, one of the most associated SNPs was in the gene GPRC6A (rs2274911, Pro91Ser, OR = 0.88, P = 1.3 × 10(-5)) near to a known risk locus for prostate cancer; other suggestive associations were noted in genes such as F13A1, ANXA4, MANSC1, and GP6. For both breast and prostate cancer, several of the most significant associations involving SNPs or gene burden scores (sum of minor alleles) were noted in genes previously reported to be associated with a cancer-related phenotype. However, only one of the associations (rs145889899 in LDLRAD1, p = 2.5 × 10(-7) only seen in African Americans) for overall breast or prostate cancer risk was statistically significant after correcting for multiple comparisons. In addition to breast and prostate cancer, other cancer-related traits were examined (body mass index, PSA level, and alcohol drinking) with a number of known and potentially novel associations described. In general, these findings do not support there being many protein coding variants of moderate to high risk for breast and prostate cancer with odds ratios over a range that is probably required for protein coding variation to play a truly outstanding role in risk heritability. Very large sample sizes will be required to better define the role of rare and less penetrant coding variation in prostate and breast cancer disease genetics.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
Publication types
MeSH terms
Grants and funding
- RC2 CA148085/CA/NCI NIH HHS/United States
- R01-CA63464/CA/NCI NIH HHS/United States
- U19 CA148537/CA/NCI NIH HHS/United States
- R01 CA063464/CA/NCI NIH HHS/United States
- R01 CA132839/CA/NCI NIH HHS/United States
- U01-CA1326792/CA/NCI NIH HHS/United States
- R37 CA054281/CA/NCI NIH HHS/United States
- R37-CA54281/CA/NCI NIH HHS/United States
- U01 HG004726/HG/NHGRI NIH HHS/United States
- RC2-CA148085/CA/NCI NIH HHS/United States
- U01-HG004726-01/HG/NHGRI NIH HHS/United States
- R01-CA132839-01/CA/NCI NIH HHS/United States
- U19-CA148537/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
